Hepatitis D cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Considering that patients who develop symptomatic hepatitis D may progress into cirrhosis, liver failure and hepatocellular carcinoma, research for an adequate therapeutic regimen and for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective.

Template:WH Template:WS